Table 2. Micronucleus tests with SET-M33L peptide in human lymphocytes.
| Compound/concentration (μg/ml) | Mean of binucleate cells containing micronuclei per 1000 cells |
||
|---|---|---|---|
| 3h − S9 | 3h + S9 | 20h − S9 | |
| vehicle (control) | 6.3 | 6.3 | 9.5 |
| SET-M33L/7.5 | 6.0 | 4.0 | 8.5 |
| SET-M33L/150 | 6.0 | NA | NA |
| SET-M33L/300 | NA | 5.5 | 8.5 |
| SET-M33L/350 | 7.0 | NA | NA |
| SET-M33L/400 | NA | 6.0 | 9.5 |
| MMC/0.2 | 28.0 | NA | NA |
| MMC/0.05 | NA | NA | 22.5 |
| COL/0.06 | 20.5 | NA | NA |
| COL/0.01 | NA | NA | 19.0 |
| CPA/10 | NA | 17.0 | NA |
The table reports the mean of binucleated cells containing micronuclei after incubation with SET-M33L or positive controls at different concentrations. Lymphocytes, stimulated to divide by addition of PHA 48 hours prior to treatment, were exposed to SET-M33L for 3 hours (h) with and without exogenous metabolic activation (S9 mix), and for 20 hours (h) without S9 mix.
MMC: Mitomycin C; COL: Colchicine; CPA: Cyclophosphamide; NA: culture not analysed for micronucleus frequency.